Literature DB >> 17953526

Interaction of calreticulin with CD40 ligand, TRAIL and Fas ligand.

K Duus1, R T Pagh, U Holmskov, P Højrup, S Skov, G Houen.   

Abstract

The molecular chaperone calreticulin has been shown to bind C1q and mannan-binding lectin (MBL), which are constituents of the innate immune defence system. C1q and MBL do not share a large sequence identity but have a similar overall molecular architecture: an N-terminal triple-helical collagen-like domain and a C-terminal globular domain with ligand-binding properties. C1q is a hetero-trimer, while MBL is a homo-trimer, but due to the presence of N-terminal cysteines they both form higher order oligomers of trimers, which are the mature functional molecules. The same molecular architecture is utilized by many other functionally diverse molecules and in this work the interaction of calreticulin with C1q and structurally similar molecules was investigated. In addition to C1q and MBL, CD40 ligand (CD40L), tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL) were found to bind calreticulin strongly. A low level or no binding was observed for adiponectin, tumour necrosis factor-alpha (TNF-alpha), CD30L, surfactant protein-A and -D and collagen VIII. The interaction with calreticulin required a conformational change in CD40L, TRAIL and FasL and showed the same characteristics as calreticulin's interaction with C1q and MBL: a time-dependent saturable binding to immobilized protein, which was initially sensitive to salt but gradually developed into a salt-insensitive interaction. Thus, the interaction requires a structural change in the interaction partner and leads to a conformational change in calreticulin itself. The implications of these results are that calreticulin may function as a general response modifier for a whole group of immunologically important proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17953526     DOI: 10.1111/j.1365-3083.2007.01999.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Serum calreticulin as a novel biomarker of juvenile idiopathic arthritis disease activity.

Authors:  Nashwa Ismail Hashaad; Rasha Mohamed Fawzy; Abeer Ahmed Abo Elazem; Mohamed Ibrahim Youssef
Journal:  Eur J Rheumatol       Date:  2017-03-01

2.  ERK1/2 and the Bcl-2 Family Proteins Mcl-1, tBid, and Bim Are Involved in Inhibition of Apoptosis During Persistent Chlamydia psittaci Infection.

Authors:  Li Li; Chuan Wang; Yating Wen; Yuming Hu; Yafeng Xie; Man Xu; Mingxing Liang; Wei Liu; Liangzhuan Liu; Yimou Wu
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

3.  Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis.

Authors:  Manuel A Pallero; Carrie A Elzie; Jiping Chen; Deane F Mosher; Joanne E Murphy-Ullrich
Journal:  FASEB J       Date:  2008-07-24       Impact factor: 5.191

Review 4.  The ever-expanding immunomodulatory role of calreticulin in cancer immunity.

Authors:  Marco de Bruyn; Valerie R Wiersma; Wijnand Helfrich; Paul Eggleton; Edwin Bremer
Journal:  Front Oncol       Date:  2015-02-20       Impact factor: 6.244

5.  TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.

Authors:  Adrien Daigeler; Christina Brenzel; Daniel Bulut; Anne Geisler; Christoph Hilgert; Marcus Lehnhardt; Hans U Steinau; Annegret Flier; Lars Steinstraesser; Ludger Klein-Hitpass; Ulrich Mittelkötter; Waldemar Uhl; Ansgar M Chromik
Journal:  J Exp Clin Cancer Res       Date:  2008-12-12

6.  Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.

Authors:  Kim L Brunekreeft; Corinna Strohm; Marloes J Gooden; Anna A Rybczynska; Hans W Nijman; Götz U Grigoleit; Wijnand Helfrich; Edwin Bremer; Daniela Siegmund; Harald Wajant; Marco de Bruyn
Journal:  Mol Cancer       Date:  2014-04-17       Impact factor: 27.401

7.  Calreticulin Binds to Fas Ligand and Inhibits Neuronal Cell Apoptosis Induced by Ischemia-Reperfusion Injury.

Authors:  Beilei Chen; Zhengzheng Wu; Jun Xu; Yun Xu
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.